MAR 3 1 2005 This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA and 21 CFR §807.92

Submitter's Name: Gocanning Technology Ltd.

Address:

6F-1, No. 188, Sec. 3, Tatung Rd., Hsichih City, Taipei, Taiwan

Phone:

TEL: 001-886-2-86471618

Fax:

FAX: 001-886-2-86472653

Contact:

Mr. TSUNG-Kun Su, General Manager

2.0 Device Name

Trade Name:

GOCANNING GLS-700 e-Pulse Analysis Monitor

Model No.: GLS-700

Common Name:

Non-Invasive Blood Pressure Monitor

Classification name: System, Measurement, Blood-Pressure, Non-Invasive

3.0 Classification:

Class II

4.0 Predicate Device:

The predicate device is the Rossmax Automatic Blood Pressure Monitor(K021225) marketed by ROSSMAX INTERNATIONAL LTD.

5.0 Device Description: GOCANNING GLS-700 e-Pulse Analysis Monitor is designed to measure the systolic and diastolic blood pressure, and pulse rate(heart

of an individual).

6.0 Intended Use:

GOCANNING GLS-700 e-Pulse Analysis Monitor is intended to measure human's Systolic, Diastolic blood pressure and pulse rate. All

values can be read out in one LCD DISPLAY.

7.0 Performance

Summary:

In terms of operating specification, Safety & EMC requirements, the

device conforms to applicable standards included EN-1060-1,

EN-1060-3, ANSI/AAMI SP-10, IEC 60601-1 and IEC 60601-1-2

requirements.

8. Conclusions:

The GOCANNING GLS-700 e-Pulse Analysis Monitor have the same intended use and similar technological characteristics as Rossmax Automatic Blood Pressure Monitor(K021225) marketed by ROSSMAX INTERNATIONAL LTD. Moreover, bench testing contained in this submission and 'inical testing supplied demonstrate that any differences in their technological characteristics do not raise and new questions of safety or effectiveness. Thus, the GOCANNING GLS-700 e-Pulse Analysis Monitor is substantially equivalent to the predicate devices.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 3 1 2005

Gocanning Technology, Ltd. c/o Ms. Jennifer Reich Harvest Consulting Corp. 3892 South America Trail West Flagstaff, AZ 86001

Re: K043352

Trade Name: GLS-700 e-Pulse Analysis Monitor

Regulation Number: 21 CFR 870.1130

Regulation Name: Noninvasive Blood Pressure Measurement System

Regulatory Class: II (two) Product Code: DXN Dated: March 10, 2005 Received: March 15, 2005

Dear Ms. Reich:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Page 2 - Ms. Jennifer Reich

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K043352	
Device Name: GLS-700 e-Pulse Analysis Monitor Gocanning Technology Ltd.	
Indications For Use:	
GLS-700 e-Pulse Analysis Monitor is used to meas	sure automatically human's Systolic,
The intended for use of this over-the-counter device	is for adult of age 18 and above.
Prescription Use AND/OR (Part 21 CFR 801 Subpart D)	Over-The-Counter UseV (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)	
Concurrence of CDRH, Office of Device Evaluation (ODE)	
(Division Sign-Off) Division of Cardiovascular [510(k) Number KOY3	